EP Patent

EP3922246A1 — Cenicriviroc for the treatment of fibrosis

Assigned to Tobira Therapeutics Inc · Expires 2021-12-15 · 4y expired

What this patent protects

The present disclosure relates to pharmaceutical compositions containing cenicriviroc, methods for the preparation thereof, and their use in the treatment of inflammation and connective tissue diseases and disorders, especially fibrosis.

USPTO Abstract

The present disclosure relates to pharmaceutical compositions containing cenicriviroc, methods for the preparation thereof, and their use in the treatment of inflammation and connective tissue diseases and disorders, especially fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3922246A1
Jurisdiction
EP
Classification
—
Expires
2021-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Tobira Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.